Shanghai Henlius Biotech Inc. has announced IND approval by the FDA for HLX-42 for injection, an antibody-drug conjugate (ADC) developed under a collaboration between Henlius and Medilink Therapeutics.
Why cancer? The mechanisms that drive and maintain tumorigenesis are still a mystery. This is a play with different actors who have different roles in several contexts. One of these scenarios is represented by genetic and epigenetic conditions that determine the early trajectories of cancer cells. In addition, different mechanisms will control phenotypes and states that can take one or another direction toward cancer.
Shanghai Henlius Biotech Inc. has announced IND approval by the FDA for HLX-42 for injection, an antibody-drug conjugate (ADC) developed under a collaboration between Henlius and Medilink Therapeutics.
Medigene AG has announced a prioritization of its pipeline as it advances its differentiated T-cell receptor engineered T cell (TCR-T) therapies for solid tumors.
Myricx Bio (Myricx Pharma Ltd.) and Wuxi Biologics Co. Ltd. have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on Wuxi Bio's integrated technology platforms.
Medicovestor Inc. has successfully completed an oversubscribed seed financing round with the aim of advancing its antibody-drug conjugate (ADC) platforms and drug candidates.
Voltron Therapeutics Inc., a portfolio company of Lucius Partners LLC, has finalized the protocol for a preclinical dose-ranging efficacy study of VTX-0P4, a protein-based cancer vaccine targeting prostate stem cell antigen (PSCA), a key target in the treatment of prostate cancer.
Researchers from Apeximmune Therapeutics Inc. presented the discovery and preclinical evaluation of AIM-104, a novel potent pan-allele anti-SIRPα antibody for the treatment of cancer.
Work at Laekna Therapeutics Shanghai Co. Ltd. has led to the discovery of a potent leukocyte immunoglobulin-like receptor subfamily B member 1/2 (LILRB1/LILRB2) antagonistic bispecific antibody, LAE-111, with improved antitumor activity.
RSS
